Advertisement
AXON vs NTLA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and NTLA is a Hold.
NTLA in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 15, 2026
NTLA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 38 cases where NTLA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NTLA just turned positive on October 01, 2026. Looking at past instances where NTLA's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
The 10-day moving average for NTLA crossed bullishly above the 50-day moving average on October 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +11.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in 201 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 104 of 128 cases where NTLA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 51 cases where NTLA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTLA as a result. In 82 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
NTLA moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for NTLA moved below the 200-day moving average on September 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.199) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AXON | NTLA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 63 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 71 | 100 | |
SMR RATING 1..100 | 81 | 98 | |
PRICE GROWTH RATING 1..100 | 64 | 60 | |
P/E GROWTH RATING 1..100 | 37 | 100 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTLA's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for AXON (87). This means that NTLA’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as NTLA (100). This means that AXON’s stock grew similarly to NTLA’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as NTLA (98). This means that AXON’s stock grew similarly to NTLA’s over the last 12 months.
NTLA's Price Growth Rating (60) in the Biotechnology industry is in the same range as AXON (64). This means that NTLA’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for NTLA (100). This means that AXON’s stock grew somewhat faster than NTLA’s over the last 12 months.
| AXON | NTLA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | N/A |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| Momentum ODDS (%) | N/A | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 64% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 88% |
| TrendMonth ODDS (%) | 1 day ago 71% | 1 day ago 77% |
| Advances ODDS (%) | 5 days ago 74% | 5 days ago 78% |
| Declines ODDS (%) | 1 day ago 70% | 1 day ago 88% |
| BollingerBands ODDS (%) | N/A | 1 day ago 89% |
| Aroon ODDS (%) | 1 day ago 58% | 1 day ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while NTLA’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- NTLA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 3 bearish.
- NTLA’s TA Score: 5 bullish, 5 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -1.26% price change this week, while NTLA (@Biotechnology) price change was -3.72% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -7.64%. For the same industry, the average monthly price growth was -12.28%, and the average quarterly price growth was -19.41%.
The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -14.96%, and the average quarterly price growth was -16.57%.
Reported Earning Dates
AXON is expected to report earnings on Nov 10, 2026.
NTLA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Aerospace & Defense (-7.64% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-6.67% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement